Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918637 | 1.00 | NOS1 (0.38) | NOS1NOS3NOS2LTA4HPRKCA | |
| SCHEMBL186690 | 1.00 | NOS1 (0.38) | NOS1NOS3NOS2LTA4HPRKCA | |
| Hydrochloric Acid SCHEMBL918636 | 0.98 | NOS1 (0.37) | NOS1NOS3NOS2LTA4HPRKCA | |
| Hydrochloric Acid SCHEMBL4555756 | 0.98 | NOS1 (0.37) | NOS1NOS3NOS2LTA4HPRKCA | |
| Hydrochloric Acid SCHEMBL3104040 | 0.98 | NOS1 (0.37) | NOS1NOS3NOS2LTA4HPRKCA | |
| Hydrochloric Acid SCHEMBL8601086 | 0.92 | NOS1 (0.35) | NOS1NOS3NOS2LTA4HPRKCA | |
| SCHEMBL3294154 | 0.84 | NOS1 (0.42) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL569252 | 0.84 | NOS1 (0.39) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL5692825 | 0.84 | DGAT1 (0.32) | NOS1NOS3NOS2PRKCASLC7A5 | |
| SCHEMBL31295917 | 0.83 | SLC7A5 (0.33) | NOS1NOS3NOS2LTA4HSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 714 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462826-B | Pseudo peptide compound and preparation method and application thereof | 成都普康唯新生物科技有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119462826-A | Pseudo peptide compound and preparation method and application thereof | 成都普康唯新生物科技有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119470406-A | Phthalic dicarboxaldehyde disinfectant concentration detection test paper and preparation method thereof | 山东新华莎罗雅生物技术有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-118239879-A | Method for preparing 3-substituted oxindole, dihydroisoindigo and tetra-substituted ethane based on primary amine and application of primary amine | 泰山学院 | 2024-06-25 | — | — | CN | claimed |
| CN-118005916-A | Modified polyamino acid derivative with conformational regulating capability, preparation and application thereof | 四川大学 | 2024-05-10 | — | — | CN | claimed |
| US-11332495-B2 | Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix | RK Pharma Solutions LLC (US) | 2022-05-17 | — | — | US | claimed |
| US-20210094984-A1 | Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix | CITIBANK, N.A. | 2021-04-01 | — | — | US | claimed |
| CN-102617503-B | Novel synthetic method of (S)-3-morpholinyl carboxylic acid | CHAINPHARM BIO MEDICAL CO LTD | 2014-05-07 | — | — | CN | claimed |
| CN-103421088-A | Solid-phase synthesis method for monocyte migration inhibitory factor | GUANGDONG 8PLUS1 MEDICINE CO LTD | 2013-12-04 | — | — | CN | claimed |
| CN-102617503-A | Novel synthetic method of (S)-3-morpholinyl carboxylic acid | CHAINPHARM CO LTD | 2012-08-01 | — | — | CN | claimed |
| US-20250346578-A1 | BIS(DIAZIRINE) DERIVATIVES AS PHOTO-CROSSSLINKER FOR TREATING CORNEAL ECTATIC DISORDERS | AVEDRO INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | Maxymune Therapeutics, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12344598-B2 | Bis(diazirine) derivatives as photo-crosslinker for treating corneal ectatic disorders | AVEDRO, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| CN-1168673-A | New dipeptide p-amidinobenzylamides with N-terminal sulfonyl or aminosulfonyl radicals | BASF AG (DE) | 1997-12-24 | — | — | CN | disclosed |
| EP-0733066-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015979-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
| US-4656186-A | FLUORESCENCE | NIPPON PETROCHEMICALS CO., LTD. (JP) | 1987-04-07 | — | — | US | disclosed |
| EP-0200218-A2 | Tetrapyrrole therapeutic agents | Nippon Petrochemicals Co., Ltd. (JP) | 1986-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346578-A1 | BIS(DIAZIRINE) DERIVATIVES AS PHOTO-CROSSSLINKER FOR TREATING CORNEAL ECTATIC DISORDERS | SYMPK, DSG1, JUP | NOS1 1028/4885NOS3 756/4885NOS2 595/4885 |
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | NOS1 1158/4885NOS3 2165/4885NOS2 1764/4885 |
| US-11332495-B2 | Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix | PEPD, DNPEP, PREP | NOS1 2705/4885NOS3 2932/4885NOS2 2753/4885 |
| US-20210094984-A1 | Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix | PEPD, DNPEP, PREP | NOS1 2731/4885NOS3 2948/4885NOS2 2779/4885 |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | SLC43A1, SLC7A1, SLC1A5 | NOS1 1158/4885NOS3 2165/4885NOS2 1764/4885 |
| US-12344598-B2 | Bis(diazirine) derivatives as photo-crosslinker for treating corneal ectatic disorders | PSEN1, GRIK1, DSG1 | NOS1 599/4885NOS3 1397/4885NOS2 866/4885 |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | NOS1 1158/4885NOS3 2165/4885NOS2 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.